CTNM

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for neuroscience and immunology disorders. Headquartered in Boston, Massachusetts, the company leverages its expertise in protein science and structural biology to identify and develop small molecule drugs targeting previously undruggable proteins. Contineum's pipeline includes programs addressing serious neurological conditions and immune-mediated diseases with significant unmet medical needs. The company was formed through the merger of multiple research-driven organizations and maintains a discovery-focused approach to drug development.